Angiotensin II receptor blockers

摘要: The ARBs have very similar clinical profiles. They do, however, different pharmacokinetic profiles, which may lead to some differences in efficacy. newer agents irbesartan, candesartan, telmisartan, and olmesartan longer half-lives durations of action than the older losartan valsartan (5). Twenty-four–hour blood pressure control could be more readily achievable with agents. Losartan need administered twice daily patients needing greater antihypertensive effects, whereas no added benefit when once daily. Of course, a once-daily product is always preferred. Several double-blind, head-to-head comparative trials evaluated relative efficacy mild moderate hypertension. net result that longer-acting effective at providing 24-hour control. But, as also mentioned, metaanalysis 43 comparing effects found comparable efficacies within ARB class (4, 5). Whether reported are clinically relevant regarding morbidity mortality has not been determined. When evaluating among ARBs, their current future places therapy for unlabeled uses must considered. use heart failure, combination ACE inhibitors alone standard therapy. only studies completed involved long-term follow-up endpoints. Neither agent can replace first-line therapy, but both remain rational alternative unable tolerate inhibitors. Candesartan currently being this same use.